Lykos takes an­oth­er hit as ICER lays out 'in­suf­fi­cien­t' ev­i­dence for MD­MA-based treat­ment

A key in­de­pen­dent drug pric­ing or­ga­ni­za­tion has con­clud­ed that the avail­able ev­i­dence for Lykos Ther­a­peu­tics’ MD­MA-as­sist­ed psy­chother­a­py is “in­suf­fi­cient” and it can’t be com­pared to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER